For the year ending 2025-12-31, FDMT has $566,711K in assets. $61,047K in debts. $60,241K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 60,241 | |||
| Marketable securities | 342,414 | |||
| Prepaid expenses and other current assets | 10,479 | |||
| Total current assets | 413,134 | |||
| Marketable securities, long-term | 111,379 | |||
| Total property and equipment | 36,146 | |||
| Less accumulated depreciation and amortization | 21,279 | |||
| Property and equipment, net | 14,867 | |||
| Operating lease right-of-use assets, net | 18,143 | |||
| Other assets | 9,188 | |||
| Total assets | 566,711 | |||
| Accounts payable | 11,159 | |||
| Accrued and other current liabilities | 26,874 | |||
| Deferred revenue | 360 | |||
| Operating lease liabilities, current portion | 5,592 | |||
| Total current liabilities | 43,985 | |||
| Deferred revenue, net of current portion | 745 | |||
| Derivative liability | 358 | |||
| Operating lease liabilities, long-term portion | 15,821 | |||
| Other liabilities | 138 | |||
| Total liabilities | 61,047 | |||
| Common stock, 0.0001 par value, 300,000,000 shares authorized at december 31, 2025 and 2024 57,607,874 and 45,793,942 shares issued and outstanding at december 31, 2025 and 2024, respectively | 6 | |||
| Additional paid-in-capital | 1,221,235 | |||
| Accumulated other comprehensive gain | 727 | |||
| Accumulated deficit | -716,304 | |||
| Total stockholders' equity | 505,664 | |||
| Total liabilities and stockholders' equity | 566,711 | |||
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)